Diffuse Large B-Cell Lymphoma, NOS · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-OCC-GLYPHOSATE-PREVENTION-INTENSIFIED-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB — v0.3 IARC 2A probable-carcinogen batch (glyphosate). IARC Group 2A probable — limited human evidence; clinical recommendation more conservative than Group 1. IARC Monograph 112 (2015) is the canonical evidence anchor; cited in notes only (not yet a separate SRC entity in KB). Cross-regulatory disagreement (EFSA / EPA / Health Canada / JMPR concluded "unlikely to pose carcinogenic risk") documented explicitly in patient counseling. Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode exemption.

Used By

Red flag

RF-OCC-GLYPHOSATE-PREVENTION - Documented historical occupational exposure to glyphosate-based herbicides (most notably...